期刊
GUT MICROBES
卷 10, 期 3, 页码 334-357出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/19490976.2018.1526583
关键词
Ulcerative colitis; fructans; inulin; FOS; intestinal microbiota; pyrosequencing; butyrate
资金
- Canadian Institutes of Health Research [CIHR MOP-81396]
- Crohn's and Colitis Foundation of Canada [CCFC G599000767]
- Beneo-Orafti
- Canadian Association of Gastroenterology-CIHR-Abbott
The intestinal microbiota is involved in ulcerative colitis (UC) pathogenesis. Prebiotics are hypothesized to improve health through alterations to gut microbiota composition and/or activity. Our aim was therefore to determine if inulin-type fructans induce clinical benefits in UC, and identify if benefits are linked to compositional and/or functional shifts of the luminal (fecal) and mucosal (biopsy) bacterial communities. Patients (n=25) with mild/moderately active UC received 7.5g (n=12) or 15g (n=13) daily oral oligofructose-enriched inulin (Orafti (R) Synergy1) for 9weeks. Total Mayo score, endoscopic activity and fecal calprotectin were assessed. Fecal and mucosal bacterial communities were characterized by 16S rRNA tag sequencing, and short chain fatty acids (SCFA) production were measured in fecal samples. Fructans significantly reduced colitis in the high-dose group, with 77% of patients showing a clinical response versus 33% in the low-dose group (P=0.04). Fructans increased colonic butyrate production in the 15g/d dose, and fecal butyrate levels were negatively correlated with Mayo score (r=-0.50; P=0.036). The high fructan dose led to an increased Bifidobacteriaceae and Lachnospiraceae abundance but these shifts were not correlated with improved disease scores. In summary, this pilot study revealed that 15g/d dose inulin type fructans in UC produced functional but not compositional shifts of the gut microbiota, suggesting that prebiotic-induced alterations of gut microbiota metabolism are more important than compositional changes for the benefits in UC. The findings warrant future well-powered controlled studies for the use of beta-fructans as adjunct therapy in patients with active UC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据